These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
610 related articles for article (PubMed ID: 27111043)
1. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Tessoulin B; Ceballos P; Chevallier P; Blaise D; Tournilhac O; Gauthier J; Maillard N; Tabrizi R; Choquet S; Carras S; Ifrah N; Guillerm G; Mohty M; Tilly H; Socie G; Cornillon J; Hermine O; Daguindau É; Bachy E; Girault S; Marchand T; Oberic L; Reman O; Leux C; Le Gouill S Bone Marrow Transplant; 2016 Sep; 51(9):1184-90. PubMed ID: 27111043 [TBL] [Abstract][Full Text] [Related]
2. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794 [TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N; Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go? Le Gouill S; Mohty M; Guillaume T; Gastinne T; Moreau P Semin Hematol; 2011 Jul; 48(3):227-39. PubMed ID: 21782065 [TBL] [Abstract][Full Text] [Related]
5. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414 [TBL] [Abstract][Full Text] [Related]
6. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI; Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879 [TBL] [Abstract][Full Text] [Related]
7. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. Fenske TS; Zhang MJ; Carreras J; Ayala E; Burns LJ; Cashen A; Costa LJ; Freytes CO; Gale RP; Hamadani M; Holmberg LA; Inwards DJ; Lazarus HM; Maziarz RT; Munker R; Perales MA; Rizzieri DA; Schouten HC; Smith SM; Waller EK; Wirk BM; Laport GG; Maloney DG; Montoto S; Hari PN J Clin Oncol; 2014 Feb; 32(4):273-81. PubMed ID: 24344210 [TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970 [TBL] [Abstract][Full Text] [Related]
9. Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma. Fukano R; Mori T; Fujita N; Kobayashi R; Mitsui T; Kato K; Suzuki R; Suzumiya J; Fukuda T; Shindo M; Maseki N; Shimoyama T; Okada K; Inoue M; Inagaki J; Hashii Y; Sato A; Tabuchi K Int J Hematol; 2019 Dec; 110(6):723-728. PubMed ID: 31620968 [TBL] [Abstract][Full Text] [Related]
10. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651 [TBL] [Abstract][Full Text] [Related]
11. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680 [TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A; Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922 [TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394 [TBL] [Abstract][Full Text] [Related]
14. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754 [TBL] [Abstract][Full Text] [Related]
15. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515 [TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT). Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689 [TBL] [Abstract][Full Text] [Related]
17. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience. Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652 [TBL] [Abstract][Full Text] [Related]
18. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043 [TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369 [TBL] [Abstract][Full Text] [Related]
20. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]